PTG-300
Phase 2Small molecule
Protagonist TherapeuticsPTG-300 is one of 70 small molecule programs targeting Polycythemia Vera. It is currently in Phase 2.
3
Indications
6
Total Trials
0
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Polycythemia Vera
#DrugCompanyPhaseTrials
1Droxia
TTheravia
Approved
BESREMI
PPharmaEssentia
Approved
Jakafi
IncytePhase 3
Trisenox
CCephalon
Approved
Ojjaara
GGlaxo Dba Glaxosmithkline
Approved
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
PEG-Intron
Merck & Co.Phase 3
Duvyzat
ItalfarmacoPhase 3
Best Available Therapy
NovartisPhase 3
Bayer Aspirin
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Beta-Thalassemia2 trials
Polycythemia Vera2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PTG-300. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company